Aster Capital Management
PHAT icon

Aster Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Aster Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$44.1K Buy
6,036
+5,528
+1,088% +$52.1K 0.02% 595
2026
Q2 		$5.51K Buy
+508
New +$5.8K ﹤0.01% 715
2025
Q1 		– Sell
-15
Closed -$122 – 1582
2024
Q4 		$122 Sell
15
-30
-67% -$372 ﹤0.01% 1069
2024
Q3 		$814 Buy
+45
New +$629 ﹤0.01% 1031

Other funds holding PHAT

Medicxi Ventures Management
Medicxi Ventures Management St. Helier, Jersey $127M AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $8.36B AUM 14.46% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Catalys Pacific
Catalys Pacific Tokyo, Japan $210M AUM 33.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aster Capital Management's PHAT Position: Q3 2026 in Review

Aster Capital Management increased its Phathom Pharmaceuticals (PHAT) stake by 1,088% in Q3 2026, buying an estimated $52.1K and bringing the position to 6,036 shares worth $44.1K. The position accounts for 0.02% of the portfolio, ranked #595.

Aster Capital Management first reported a position in PHAT in Q3 2024 and has held it in 4 quarters since. 109 funds tracked by Wall St. Rank hold PHAT as of Q3 2026.

  • Aster Capital Management held 6,036 shares of Phathom Pharmaceuticals worth $44.1K as of Q3 2026.
  • Aster Capital Management bought 5,528 Phathom Pharmaceuticals shares in Q3 2026, an estimated $52.1K.
  • Phathom Pharmaceuticals made up 0.02% of Aster Capital Management's portfolio in Q3 2026, its #595 holding.
  • Aster Capital Management first reported a position in Phathom Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • 109 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2026.

Based on Aster Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.